ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Leede Jones Gable out with target

<< Previous

Bullboard Posts

Next >>

Comment by retiredcopon May 12, 2023 11:03am

188 Views

Post# 35445414

RE:RE:RE:Leede Jones Gable out with target

I know and realize we need a lot of
money to get pmn310 through clinicals , but we also need money to get the als and pd treatments to clinicals . The conversion rate was just something that was brought to my attention by another long long time investor. Helped
me put things into perspective again on where we were and where we are going .. possibly !

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec